Back to top
more

The Cooper Companies (COO)

(Real Time Quote from BATS)

$93.59 USD

93.59
776,707

+0.98 (1.06%)

Updated Jul 31, 2024 11:16 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 21% (199 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

The Cooper Companies Inc (COO), based in Pleasanton, CA, is a specialty medical device company operating on a global basis. Cooper has two business segments- CooperVision (CVI) and CooperSurgical (CSI). CooperVision manufactures and sells a wide range of contact lenses. CooperVision develops manufactures and markets a broad range of single-use, two-week and monthly contact lenses, featuring advanced materials and optics. The company’s products are primarily designed for solving vision challenges like astigmatism, presbyopia and ocular dryness. CooperSurgical sells a variety of medical devices and surgical instruments that are primarily utilized by gynecologists and obstetricians. This strategic business unit has pursued a strategy of consolidation by acquiring critical treatment niches in a fragmented market.

HSIC vs. COO: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

HSIC vs. COO: Which Stock Is the Better Value Option?

Cooper Companies (COO) Q2 Earnings Top Estimates, '21 View Up

by Zacks Equity Research

Cooper Companies' (COO) fiscal second-quarter 2021 earnings reflect solid segmental performance.

Abbott (ABT) Downgrades 2021 Outlook on Lower Testing Demand

by Zacks Equity Research

Abbott's (ABT) revised 2021 forecast continues to reflect strong, double-digit EPS growth despite lower COVID-19 testing demand.

Myriad Genetics (MYGN) Sells myPath to Focus on Core Units

by Zacks Equity Research

Myriad Genetics' (MYGN) new divesture will provide the company with growth capital for future investments.

Quest Diagnostics (DGX) Buys Outreach Lab, Widens Midwest Base

by Zacks Equity Research

Mercy's outreach laboratory services are set to get integrated into Quest Diagnostics' (DGX) full-service laboratory in Lenexa, KS.

Integra (IART) Tissue Technologies Rebounds Amid Supply Woe

by Zacks Equity Research

Integra's (IART) CSS segment too reflects a gradual recovery in procedure-based market as well as an improvement in hospital capital spending during the first quarter.

Walgreens' (WBA) New Partnerships Aid, Retail Sales Dip

by Zacks Equity Research

Walgreens Boots' (WBA) response toward combatting the pandemic - conducting COVID-19 tests at various locations and actively participating in vaccinating residents and staff - is impressive.

Illumina (ILMN) Expands NIPT Offering With New Collaboration

by Zacks Equity Research

Illumina's (ILMN) VeriSeq NIPT Solution v2 provides accurate, consistent and scalable end-to-end genome-wide noninvasive prenatal testing.

Cooper Companies (COO) Unit's Ortho-K Lens Receives CE Mark

by Zacks Equity Research

Cooper Companies' (COO) unit CooperVision's latest orthokeratology contact lens becomes the latest myopia control product to gain European approval.

Here's Why You Should Add STERIS (STE) to Your Portfolio

by Zacks Equity Research

Investors are optimistic about STERIS (STE) owing to strong segmental performance and huge growth potential in healthcare and pharmaceutical industries.

Cooper Companies (COO) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

Cooper Companies' (COO) fiscal second-quarter results are likely to reflect segmental strength.

Myriad Genetics' (MYGN) GeneSight Test Rollout Initiated by IPM

by Zacks Equity Research

Myriad Genetics' (MYGN) GeneSight testing distribution initiated through IPM will help clinicians and patients assess individual's response to certain medications.

The Cooper Companies (COO) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

The Cooper Companies (COO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Cooper Companies (COO) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

The Cooper Companies (COO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Masimo (MASI), Spacelabs Team Up to Enhance Patient Outcome

by Zacks Equity Research

Masimo's (MASI) extension of partnership with Spacelabs is expected to provide better patient outcomes with the accessibility of patient monitoring solutions.

Here's Why You Should Add Inogen (INGN) to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Inogen (INGN) on its direct-to-customer business model and a strong product portfolio.

Veeva (VEEV) Enhances Clinical Trial Management via Vault CTMS

by Zacks Equity Research

Veeva's (VEEV) Vault CTMS application is expected to aid global organizations to advance study execution while ensuring compliance.

Here's Why You Should Add DaVita (DVA) to Your Portfolio Now

by Zacks Equity Research

Investor confidence is high on the DaVita (DVA) stock, courtesy of its solid prospects.

    STERIS (STE) to Report Q4 Earnings: What's in the Cards?

    by Zacks Equity Research

    STERIS (STE) is likely to have continued to gain from the robust demand of PPE and COVID-19-related products in Q4.

    Merit Medical (MMSI) Q1 Earnings and Revenues Beat Estimates

    by Zacks Equity Research

    Merit Medical (MMSI) benefits from growth in revenues at the Cardiovascular segment in Q1.

    DaVita (DVA) Q1 Earnings Beat Estimates, Revenues Miss Mark

    by Zacks Equity Research

    DaVita's (DVA) net dialysis and related lab-patient service revenues rise in Q1.

    McKesson (MCK) to Report Q4 Earnings: What's in the Offing?

    by Zacks Equity Research

    McKesson's (MCK) fiscal fourth-quarter results are likely to reflect solid show by U.S. Pharmaceutical and Specialty Solutions segment.

    DexCom (DXCM) Q1 Earnings and Revenues Surpass Estimates

    by Zacks Equity Research

    DexCom's (DXCM) first-quarter results benefit from domestic and international revenue growth.

    ABIOMED (ABMD) Earnings and Revenues Beat Estimates in Q4

    by Zacks Equity Research

    ABIOMED's (ABMD) international and U.S. Impella revenues improve in Q4.

    Surmodics (SRDX) Q2 Earnings Beat Estimates, Revenues Miss

    by Zacks Equity Research

    Surmodics (SRDX) records higher revenues in both its core units in the fiscal second quarter.